-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
NASDAQ: $CKPT Introduction Checkpoint Therapeutics, a leading biopharmaceutical company, recently made a significant announcement regarding the FDA acceptance of the Biologics License Application (BLA) resubmission of Cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. This development marks a crucial milestone in the ongoing efforts to provide effective treatment options for patients battling this…
-
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine; PDUFA goal date is January 31 2025
NASDAQ: $AXSM Axsome Therapeutics, a leading biopharmaceutical company, has recently announced the exciting news that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. With the FDA acceptance of the NDA resubmission, Axsome Therapeutics is one step closer to…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: $STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 10-16, 2023
December 10, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/10/2023 AUTL 21.1 4,281 $4.36 Conference 12/10/2023 BLUE 26.9 18,165 $2.86 Conference 12/10/2023 BMEA 43.0 49,731 $16.89 Announcement 12/11/2023 COGT 28.9 11,224 $8.64 Conference 12/11/2023 BLUE 26.9 18,165 $2.86 Conference 12/11/2023 HARP 35.3 295 $8.94 Conference 12/14/2023 BCYC 24.0 2,878…
-
Kura Oncology | Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
NASDAQ: $KURA SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: $KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s…
-
Calliditas Therapeutics | The FDA Decision To Convert The Accelerated Approval of Calliditas Therapeutics’ Tarpeyo To Full Approval, December 20, 2023
NASDAQ: CALT 1. Introduction to Calliditas Therapeutics and Tarpeyo Calliditas Therapeutics is a renowned pharmaceutical company focused on developing innovative therapies to address unmet medical needs. One of their notable products is Tarpeyo, a drug designed to provide significant benefits to patients suffering from a specific medical condition. The accelerated approval granted by the FDA…
-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
Vanda Pharmaceuticals | Announces U.S. FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
NASDAQ: VNDA 1. Introduction to Vanda Pharmaceuticals’ new drug application for Tradipitant Vanda Pharmaceuticals, a leading biopharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Tradipitant, a potential breakthrough treatment for gastroparesis. This acceptance marks a significant milestone in Vanda Pharmaceuticals’ efforts…
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: $NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…